Advanced

alpha-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies

Ballard, Clive; Jones, Emma L.; Londos, Elisabet LU ; Minthon, Lennart LU ; Francis, Paul and Aarsland, Dag (2010) In International Psychogeriatrics 22(2). p.321-327
Abstract
Background: Dementia with Lewy bodies (DLB) accounts for 15-20%, of the millions of people worldwide with dementia. Accurate diagnosis is essential to avoid harm and optimize clinical management. There is therefore an urgent need to identify reliable biomarkers. Methods: Mass spectrometry was used to determine the specificity of antibody alpha-synuclein (211) for alpha-synuclein. Using gel electrophoresis we measured protein levels detected by alpha-synuclein specific antibodies in the cerebrospinal fluid (CSF) of DLB patients and compared them to age matched controls. Results: A 24 kDa band was detected using alpha-synuclein specific antibodies which was significantly reduced in the CSF of DLB patients compared to age matched controls (p... (More)
Background: Dementia with Lewy bodies (DLB) accounts for 15-20%, of the millions of people worldwide with dementia. Accurate diagnosis is essential to avoid harm and optimize clinical management. There is therefore an urgent need to identify reliable biomarkers. Methods: Mass spectrometry was used to determine the specificity of antibody alpha-synuclein (211) for alpha-synuclein. Using gel electrophoresis we measured protein levels detected by alpha-synuclein specific antibodies in the cerebrospinal fluid (CSF) of DLB patients and compared them to age matched controls. Results: A 24 kDa band was detected using alpha-synuclein specific antibodies which was significantly reduced in the CSF of DLB patients compared to age matched controls (p < 0.05). Further analysis confirmed that even DLB patients with mild dementia showed significant reductions in this protein in comparison to controls. Conclusions: The current study emphasizes the necessity for further studies of CSF alpha-synuclein as a biomarker of DLB and extends our previous knowledge by establishing a potential relationship between alpha-synuclein and the severity of cognitive impairment. The identification of this 24 kDa protein is the next important step in these studies. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
biomarkers, cognitive decline
in
International Psychogeriatrics
volume
22
issue
2
pages
321 - 327
publisher
Cambridge University Press
external identifiers
  • wos:000275132800018
  • scopus:77950567700
ISSN
1741-203X
DOI
10.1017/S1041610209991049
language
English
LU publication?
yes
id
9d7d3c1c-2c90-4303-be79-f489dc2127c4 (old id 1589563)
date added to LUP
2010-04-20 10:44:37
date last changed
2018-05-29 11:25:55
@article{9d7d3c1c-2c90-4303-be79-f489dc2127c4,
  abstract     = {Background: Dementia with Lewy bodies (DLB) accounts for 15-20%, of the millions of people worldwide with dementia. Accurate diagnosis is essential to avoid harm and optimize clinical management. There is therefore an urgent need to identify reliable biomarkers. Methods: Mass spectrometry was used to determine the specificity of antibody alpha-synuclein (211) for alpha-synuclein. Using gel electrophoresis we measured protein levels detected by alpha-synuclein specific antibodies in the cerebrospinal fluid (CSF) of DLB patients and compared them to age matched controls. Results: A 24 kDa band was detected using alpha-synuclein specific antibodies which was significantly reduced in the CSF of DLB patients compared to age matched controls (p &lt; 0.05). Further analysis confirmed that even DLB patients with mild dementia showed significant reductions in this protein in comparison to controls. Conclusions: The current study emphasizes the necessity for further studies of CSF alpha-synuclein as a biomarker of DLB and extends our previous knowledge by establishing a potential relationship between alpha-synuclein and the severity of cognitive impairment. The identification of this 24 kDa protein is the next important step in these studies.},
  author       = {Ballard, Clive and Jones, Emma L. and Londos, Elisabet and Minthon, Lennart and Francis, Paul and Aarsland, Dag},
  issn         = {1741-203X},
  keyword      = {biomarkers,cognitive decline},
  language     = {eng},
  number       = {2},
  pages        = {321--327},
  publisher    = {Cambridge University Press},
  series       = {International Psychogeriatrics},
  title        = {alpha-synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies},
  url          = {http://dx.doi.org/10.1017/S1041610209991049},
  volume       = {22},
  year         = {2010},
}